A Phase III, Randomized, Active-Comparator-Controlled, 2-period, Crossover, Double-Blind Study in China to Assess the Safety and Efficacy of Etoricoxib 120 mg Versus Ibuprofen up to 2400 mg (600 mg Q6h) in the Treatment of Patients With Primary Dysmenorrhea.

Trial Profile

A Phase III, Randomized, Active-Comparator-Controlled, 2-period, Crossover, Double-Blind Study in China to Assess the Safety and Efficacy of Etoricoxib 120 mg Versus Ibuprofen up to 2400 mg (600 mg Q6h) in the Treatment of Patients With Primary Dysmenorrhea.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2015

At a glance

  • Drugs Etoricoxib (Primary) ; Ibuprofen
  • Indications Dysmenorrhoea
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 21 Jun 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
    • 21 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 01 May 2012 Planned End Date changed from 1 Aug 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top